(Q37842506)

24 August 2017

1 reference

title

Therapeutic management of breast cancer in the elderly (English)

1 reference

24 August 2017

Philippe Bedard

3

0 references

author name string

Simon Spazzapan

1

1 reference

24 August 2017

Diana Crivellari

2

1 reference

24 August 2017

Davide Lombardi

4

1 reference

24 August 2017

Gianmaria Miolo

5

1 reference

24 August 2017

Simona Scalone

6

1 reference

24 August 2017

Andrea Veronesi

7

1 reference

24 August 2017

language of work or name

English

0 references

publication date

16 February 2011

1 reference

Expert Opinion on Pharmacotherapy

24 August 2017

published in

1 reference

24 August 2017

volume

12

1 reference

24 August 2017

issue

6

1 reference

24 August 2017

page(s)

945-960

1 reference

Cancer in older persons: an international issue in an aging world

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.540570

21 January 2018

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.540570

Patterns of care related to age of breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.540570

Comorbidities, therapy, and newly diagnosed conditions for women with early stage breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.540570

The effect of comorbidity on 3-year survival of women with primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.540570

Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.540570

Value of functional status as a predictor of mortality: results of a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.540570

Geriatric syndromes: clinical, research, and policy implications of a core geriatric concept.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.540570

Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.540570

Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.540570

Clinical epidemiology of breast cancer in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.540570

Breast cancer in the elderly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.540570

A significant proportion of elderly patients develop hormone-dependant "luminal-B" tumours associated with aggressive characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.540570

Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.540570

Breast cancer subtypes and the risk of local and regional relapse.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.540570

Gene-expression signatures in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.540570

Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.540570

Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.540570

Population-based validation of the prognostic model ADJUVANT! for early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.540570

Calibration and discriminatory accuracy of prognosis calculation for breast cancer with the online Adjuvant! program: a hospital-based retrospective cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.540570

Management of primary and advanced breast cancer in older unfit patients (medical treatment).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.540570

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.540570

Factor V Leiden mutation and thromboembolism risk in women receiving adjuvant tamoxifen for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.540570

Adjuvant endocrine therapy compared with no systemic therapy for elderly women with early breast cancer: 21-year results of International Breast Cancer Study Group Trial IV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.540570

Protective actions of tamoxifen and 4-hydroxytamoxifen against oxidative damage to human low-density lipoproteins: a mechanism accounting for the cardioprotective action of tamoxifen?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.540570

Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. The Stockholm Breast Cancer Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.540570

Cardiovascular effects of tamoxifen in women with and without heart disease: breast cancer prevention trial. National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial Investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.540570

Meta-analysis of vascular and neoplastic events associated with tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.540570

Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.540570

Coprescription of tamoxifen and medications that inhibit CYP2D6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.540570

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.540570

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.540570

A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.540570

Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.540570

Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.540570

Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.540570

American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.540570

Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.540570

Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.540570

Chemotherapy of metastatic breast cancer in the elderly. The Piedmont Oncology Association experience [see comment].

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.540570

Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.540570

Adjuvant chemotherapy in older women with early-stage breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.540570

Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.540570

Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.540570

Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.540570

Weekly paclitaxel in the adjuvant treatment of breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.540570

Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: safety data from the multicentre phase 3 randomised ELDA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.540570

Weekly paclitaxel in women age 65 and above with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.540570

Weekly paclitaxel as first-line chemotherapy in elderly advanced breast cancer patients: a phase II study of the Gruppo Italiano di Oncologia Geriatrica (GIOGer).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.540570

Taxanes in the elderly: can we gain as much and be less toxic?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.540570

Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.540570

Pegfilgrastim primary prophylaxis vs. current practice neutropenia management in elderly breast cancer patients receiving chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.540570

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.540570

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.540570

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.540570

Adjuvant/neoadjuvant trastuzumab therapy in women with HER-2/neu-overexpressing breast cancer: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.540570

Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.540570

Clinical decision making in breast cancer: TAM and aromatase inhibitors for older patients -- a jungle?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.540570

Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.540570

Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.540570

Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.540570

Results of a phase II study comparing three dosing regimens of fulvestrant in postmenopausal women with advanced breast cancer (FINDER2).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.540570

Three dose regimens of fulvestrant in postmenopausal Japanese women with advanced breast cancer: results from a double-blind, phase II comparative study (FINDER1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.540570

Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.540570

Cost effectiveness of bisphosphonates in the management of breast cancer patients with bone metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.540570

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.540570

A multicentric observational trial of pegylated liposomal doxorubicin for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.540570

Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.540570

Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.540570

Participation of patients 65 years of age or older in cancer clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.540570

Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.540570

Altered clearance of unbound paclitaxel in elderly patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.540570

Prospective evaluation of the pharmacokinetics and toxicity profile of docetaxel in the elderly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.540570

Pharmacokinetics and toxicity of weekly docetaxel in older patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.540570

Multicenter study of a frozen glove to prevent docetaxel-induced onycholysis and cutaneous toxicity of the hand

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.540570

Non-small-cell lung cancer in elderly patients: influence of age on vinorelbine oral pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.540570

International Society of Geriatric Oncology Chemotherapy Taskforce: evaluation of chemotherapy in older patients--an analysis of the medical literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.540570

Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.540570

A prospective pharmacologic evaluation of age-related toxicity of adjuvant chemotherapy in women with breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.540570

HER2 and Response to Paclitaxel in Node-Positive Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.540570

Prevalence of Renal Insufficiency in cancer patients and implications for anticancer drug management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.540570

Randomized Phase II Trial of Letrozole and Letrozole Plus Low-Dose Metronomic Oral Cyclophosphamide As Primary Systemic Treatment in Elderly Breast Cancer Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.540570

10.1517/14656566.2011.540570

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference